Press Releases

Hepion Pharmaceuticals to Participate in Upcoming January Virtual Investor Conferences
January 05, 2021

Hepion Pharmaceuticals Announces Positive Top Line Data for Low Dose CRV431 in Phase 2a 'AMBITION' Clinical Trial for Treatment of Advanced NASH
December 29, 2020

Hepion Pharmaceuticals Data Safety Monitoring Board Recommends Continuation with Final Dose Cohort in Phase 2a 'AMBITION' Clinical Trial for Treatment of Advanced NASH
December 29, 2020

Hepion Pharmaceuticals Announces FDA Clearance of IND Application for CRV431 for COVID-19
December 22, 2020

Hepion Pharmaceuticals Completes 75 mg CRV431 Dosing, Initiates 225 mg Dosing in Phase 2a 'AMBITION' Clinical Trial for NASH
December 10, 2020

Hepion Pharmaceuticals’ CRV431 Demonstrates Additional Potential Advantage in Liver Disease
December 02, 2020

Hepion Announces Closing of Public Offering of Common Stock
November 30, 2020

Hepion Pharmaceuticals Prices Public Offering
November 24, 2020

Hepion Pharmaceuticals Data Safety Monitoring Board Recommends Continuation of Phase 2a 'AMBITION' Clinical Trial for Treatment of Advanced NASH
November 18, 2020

Hepion Pharmaceuticals to Participate in the Alliance Global Partners' Virtual Healthcare Symposium
November 17, 2020